Biovie Inc. BIVI
We take great care to ensure that the data presented and summarized in this overview for BIOVIE INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BIVI
View all-
Altium Capital Management LP New York, NY3.01MShares$1.36 Million0.9% of portfolio
-
Sabby Management, LLC Upper Saddle River, NJ689KShares$310,11012.47% of portfolio
-
Vanguard Group Inc Valley Forge, PA645KShares$290,0580.0% of portfolio
-
Cvi Holdings, LLC Wilmington, DE600KShares$269,9532.37% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny347KShares$156,3300.0% of portfolio
-
Black Rock Inc. New York, NY328KShares$147,5680.0% of portfolio
-
Swisspartners Ltd. Vaduz, N2294KShares$132,4552.92% of portfolio
-
Geode Capital Management, LLC Boston, MA247KShares$111,1970.0% of portfolio
-
State Street Corp Boston, MA175KShares$78,8250.0% of portfolio
-
Northern Trust Corp Chicago, IL115KShares$51,9560.0% of portfolio
Latest Institutional Activity in BIVI
Top Purchases
Top Sells
About BIVI
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.
Insider Transactions at BIVI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 04
2024
|
Cuong V Do President & CEO |
BUY
Open market or private purchase
|
Indirect |
10,000
+2.24%
|
-
|
|
Dec 11
2023
|
Joanne Wendy Kim Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+10.17%
|
-
|
|
Dec 01
2023
|
Steve Gorlin Director |
SELL
Open market or private sale
|
Direct |
75,680
-62.01%
|
$75,680
$1.69 P/Share
|
|
Nov 30
2023
|
Cuong V Do President & CEO |
BUY
Open market or private purchase
|
Direct |
10,000
+12.7%
|
$10,000
$1.78 P/Share
|
|
Nov 09
2023
|
Richard J Berman Director |
BUY
Grant, award, or other acquisition
|
Direct |
51,830
+42.81%
|
-
|
|
Nov 09
2023
|
Robert J Hariri Director |
BUY
Grant, award, or other acquisition
|
Direct |
42,254
+50.0%
|
-
|
|
Nov 09
2023
|
Sigmund Rogich Director |
BUY
Grant, award, or other acquisition
|
Direct |
42,254
+50.0%
|
-
|
|
Nov 09
2023
|
Steve Gorlin Director |
BUY
Grant, award, or other acquisition
|
Direct |
46,358
+27.53%
|
-
|
|
Sep 05
2023
|
Steve Gorlin Director |
SELL
Open market or private sale
|
Direct |
8,560
-10.16%
|
$25,680
$3.05 P/Share
|
|
Aug 22
2023
|
Richard J Berman Director |
SELL
Open market or private sale
|
Direct |
10,805
-39.16%
|
$32,415
$3.5 P/Share
|
|
Jun 29
2023
|
Cuong V Do President & CEO |
BUY
Grant, award, or other acquisition
|
Indirect |
149,500
+25.98%
|
-
|
|
Jun 21
2023
|
Cuong V Do President & CEO |
BUY
Exercise of conversion of derivative security
|
Indirect |
41,506
+13.26%
|
-
|
|
Jun 07
2023
|
Richard J Berman Director |
SELL
Open market or private sale
|
Direct |
5,984
-20.5%
|
$29,920
$5.81 P/Share
|
|
May 22
2023
|
Richard J Berman Director |
SELL
Open market or private sale
|
Direct |
5,000
-14.62%
|
$30,000
$6.5 P/Share
|
|
Mar 28
2023
|
Richard J Berman Director |
SELL
Open market or private sale
|
Direct |
7,613
-9.53%
|
$60,904
$8.52 P/Share
|
|
Mar 27
2023
|
Richard J Berman Director |
SELL
Open market or private sale
|
Direct |
3,371
-7.46%
|
$26,968
$8.52 P/Share
|
|
Feb 16
2023
|
Joseph M Palumbo Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,476
-6.25%
|
$14,856
$6.12 P/Share
|
|
Feb 16
2023
|
Clarence N. Ahlem EVP Neuroscience Product Dev. |
SELL
Payment of exercise price or tax liability
|
Direct |
2,476
-6.25%
|
$14,856
$6.12 P/Share
|
|
Feb 16
2023
|
Joanne Wendy Kim Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,476
-5.95%
|
$14,856
$6.12 P/Share
|
|
Feb 16
2023
|
Cuong V Do President & CEO |
SELL
Payment of exercise price or tax liability
|
Indirect |
4,953
-2.11%
|
$29,718
$6.12 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 337K shares |
|---|---|
| Exercise of conversion of derivative security | 41.5K shares |
| Open market or private purchase | 20K shares |
| Open market or private sale | 101K shares |
|---|